These results also indicate that combined PD-1 and Tim-3 blockade may be beneficial in reducing T cell exhaustion and resolving the immunosuppression in AML to overcome chemotherapy resistance. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.